October 28, 2022
Read for 1 minute
Chin J, et al. Comparison of onset of action and duration of action of Pataday Once Daily Relief Extra Strength to 24-hour Claritin tablets for reduction of ocular itching in patients with allergic conjunctivitis. Presentation: Academy; October 26-29, 2022; San Diego.
Disclosures: Weisbarth is vice president of professional affairs at Alcon US Vision Care. Alcon sponsored this study.
SAN DIEGO – A comparison of OTC Claritin tablets and over-the-counter Pataday drops at 15 minutes and 24 hours found that the drops were more effective at relieving itchy eyes in patients with allergic conjunctivitis.
Rick Weisbarth, OD, FAAO, Alcon US Vision Care’s vice president of professional affairs discussed the findings of this study during an Alcon-sponsored event at the Academy 2022.
A single-center, randomized, double-masked, parallel study enrolled 58 participants with a self-reported history of ocular allergic symptoms with a positive skin test reaction to a seasonal or perennial allergen.
Participants were randomized to receive a double dose of Pataday Once Daily Relief Extra Strength (olopatadine HCl ophthalmic solution 0.7%) and a placebo tablet or a 24-hour Claritin tablet (loratadine 10 mg, Bayer Consumer Health) and a placebo drop, Weisbarth said. .
“Comparisons were made at 15 minutes of onset of activity and then over the 24-hour duration of activity,” he said.
“The conclusion is that a single dose of Pataday Extra Strength was significantly more effective than a single dose of Claritin in two cases of allergic conjunctivitis at two times,” said Weisbarth.
“Pataday is OTC, so patients have more access to the product,” he added. “It’s one of the ways we’re trying to improve the way practitioners serve their patients.”